ES2146253T3 - Peptidos de tgf-beta 1 y tgf-beta 2 biologicamente activos. - Google Patents

Peptidos de tgf-beta 1 y tgf-beta 2 biologicamente activos.

Info

Publication number
ES2146253T3
ES2146253T3 ES94907287T ES94907287T ES2146253T3 ES 2146253 T3 ES2146253 T3 ES 2146253T3 ES 94907287 T ES94907287 T ES 94907287T ES 94907287 T ES94907287 T ES 94907287T ES 2146253 T3 ES2146253 T3 ES 2146253T3
Authority
ES
Spain
Prior art keywords
tgf
beta
monomerical
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94907287T
Other languages
English (en)
Inventor
Yasushi Ogawa
David Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharmaceuticals Inc filed Critical Celtrix Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2146253T3 publication Critical patent/ES2146253T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Abstract

LA INVENCION SE REFIERE A PEPTIDOS CORRESPONDIENTES A REGIONES DE LA SECUENCIA AMINOACIDA DE TGF-{BE}1 Y TGF-{BE}2, QUE CONSERVAN, BIEN EN FORMAS MONOMERICAS O POLIMERICAS, AL MENOS ALGO DE LA ACTIVIDAD BIOLOGICA DEL TGF-{BE} RESPECTIVO DE LONGITUD COMPLETA. LA FORMA MONOMERICA DEL PEPTIDO DERIVADO DE TFG-{BE}1, COMPRENDE LA SIGUIENTE SECUENCIA AMINOACIDA: CVRQLYIDFRKDLGWKWIHEPKGYHANFCLGP. LA FORMA MONOMERICA DEL PEPTIDO DERIVADO DE TGF-{BE}2, COMPRENDE LA SIGUIENTE SECUENCIA AMINOACIDA: CLRPLYIDFKRDLGWKWIHEPKGYNANFCAGA. LOS DIMEROS PUEDEN FORMARSE POR MEDIO DE ENLACES DISULFURO ENTRE LOS RESIDUOS DE CISTEINA AMINO-TERMINALES, LOS RESIDUOS DE CISTEINA CARBOXITERMINALES, O RESIDUOS DE CISTEINA AMINO- Y CARBOXI-TERMINALES DE LAS SUBUNIDADES MONOMERICAS.
ES94907287T 1993-01-26 1994-01-21 Peptidos de tgf-beta 1 y tgf-beta 2 biologicamente activos. Expired - Lifetime ES2146253T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/009,448 US5420243A (en) 1993-01-26 1993-01-26 Biologically active TGF-β2 peptides

Publications (1)

Publication Number Publication Date
ES2146253T3 true ES2146253T3 (es) 2000-08-01

Family

ID=21737716

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94907287T Expired - Lifetime ES2146253T3 (es) 1993-01-26 1994-01-21 Peptidos de tgf-beta 1 y tgf-beta 2 biologicamente activos.

Country Status (8)

Country Link
US (2) US5420243A (es)
EP (1) EP0791011B1 (es)
JP (1) JP3763479B2 (es)
AU (1) AU685084B2 (es)
CA (1) CA2153789C (es)
DE (1) DE69424576T2 (es)
ES (1) ES2146253T3 (es)
WO (1) WO1994017099A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69233022T2 (de) 1991-11-04 2004-02-12 Genetics Institute, LLC, Cambridge Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
US20080070842A1 (en) * 1991-11-04 2008-03-20 David Israel Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435137D1 (de) 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6291206B1 (en) * 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US5955430A (en) * 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
US5780436A (en) * 1995-05-01 1998-07-14 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US5661127A (en) * 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6040431A (en) 1995-06-07 2000-03-21 Stryker Corporation Single chain analogs of the TGF-β superfamily (morphons)
JP3638614B2 (ja) * 1996-07-25 2005-04-13 ジェンザイム・コーポレーション 軟骨細胞培地組成および培養方法
EP1074620A1 (en) 1999-08-06 2001-02-07 HyGene AG Monomeric protein of the TGF-beta family
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
EP0877031A1 (en) * 1997-05-06 1998-11-11 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) TGF-Beta1 derived peptides mimicking the activity of transforming growth factor-Beta1
CA2259956A1 (en) * 1997-05-12 1998-11-19 Kyowa Hakko Kogyo Co., Ltd. Peptides promoting the activation of latent tgf-.beta. and method for screening tgf-.beta. activity regulators
US6727224B1 (en) * 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
EP1292330A1 (en) * 2000-03-31 2003-03-19 Vaccine Chip Technology APS Immunostimulating properties of a fragment of tgf- beta
US20030082233A1 (en) * 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
EP1399023B1 (en) * 2001-06-01 2008-04-30 Wyeth COMPOSITIONS FOR SYSTEMIC ADMINISTRATION OF SEQUENCES ENCODING BONE MORPHOGENETIC PROTEINS& x9;
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
MXPA04011337A (es) * 2002-05-17 2005-07-01 Wyeth Corp Portadores de acido hialuronico solidos y susceptibles de ser inyectados para la liberacion de proteinas osteogenicas.
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
BRPI0413720A (pt) * 2003-09-12 2006-10-17 Wyeth Corp bastões e pastas sólidas de fosfato de cálcio injetável para liberação de proteìnas osteogênicas
US20060166251A1 (en) * 2005-01-26 2006-07-27 Archambault Joanne M Use of sFRPs as markers of BMP activity
MX2007011591A (es) * 2005-03-30 2007-12-10 Wyeth Corp Metodo para estimular el crecimiento de cabello administrando bmps.
US20060293228A1 (en) * 2005-06-24 2006-12-28 Bhatnagar Rajendra S Therapeutic compositions and methods using transforming growth factor-beta mimics
US8691195B2 (en) * 2009-04-14 2014-04-08 Caregen Co., Ltd. Peptide having activity of transforming growth factor and production method therefor
JP5890100B2 (ja) * 2011-02-09 2016-03-22 雪印メグミルク株式会社 皮膚コラーゲン産生促進剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806523A (en) * 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4822606A (en) * 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
US5218140A (en) * 1988-08-02 1993-06-08 Union Carbide Chemicals & Plastics Technology Corporation Carbonylation reaction and catalyst therefor
CA2005120A1 (en) * 1988-12-15 1990-06-15 Anthony F. Purchio Tgf-beta 1/beta 2: a novel chimeric transforming growth factor-beta
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
JPH05501500A (ja) * 1989-10-18 1993-03-25 クリエイティブ・バイオマリキュールズ・インコーポレーテッド ＴＧＦ―βの生合成構築物

Also Published As

Publication number Publication date
US5658883A (en) 1997-08-19
AU6093294A (en) 1994-08-15
DE69424576D1 (de) 2000-06-21
EP0791011A2 (en) 1997-08-27
JPH08510443A (ja) 1996-11-05
AU685084B2 (en) 1998-01-15
EP0791011B1 (en) 2000-05-17
WO1994017099A2 (en) 1994-08-04
CA2153789C (en) 2007-04-17
US5420243A (en) 1995-05-30
JP3763479B2 (ja) 2006-04-05
DE69424576T2 (de) 2001-01-18
WO1994017099A3 (en) 1995-01-05
CA2153789A1 (en) 1994-08-04

Similar Documents

Publication Publication Date Title
ES2146253T3 (es) Peptidos de tgf-beta 1 y tgf-beta 2 biologicamente activos.
DE69841105D1 (de) Chemokine peptide, varianten, derivate und analoge. ihre verwendung in methode für die hemmung oder erhöhung von einer entzündungsreaktion
ES2192620T3 (es) Polipeptido receptor de il-13.
ATE78040T1 (de) Oligopeptide sowie zwischenprodukte und verfahren zu ihrer herstellung.
ES2134770T3 (es) Proteinas producidas por los linfocitos humanos, secuencia de adn codante para estas proteinas y aplicaciones farmaceuticas y biologicas.
DE60021497D1 (de) Menschliche, für zyklische Nukleotide spezifische Phosphodiesterase
BRPI0511005A (pt) peptìdeos oligoméricos e seu uso para o tratamento de infecções por hiv
PT938502E (pt) Metodo selectivo por acilacao
CY1111802T1 (el) Πρωτεϊνη συμμετεχουσα σε αποκατασταση γονιμοτητας φυτου με κυτταροπλασματικη ανδροστειροτητα και γονιδιο που την κωδικοποιει
ATE509886T1 (de) Peptidnanostrukturen, verfahren zu deren herstellung und verwendung
ES2180948T3 (es) Peptido que proviene de una forma soluble de la acetilcolinesterasa, activo como modulador del canal.
NO20073914L (no) Biologisk aktive peptider
BR9808376A (pt) Moléculas bi- ou multifuncionais com base em uma armação de dendroaspina
CY1109946T1 (el) Τροποποιημενα πεπτιδια και η χρηση τους για τη θεραπεια αυτοανοσων νοσων
CR7058A (es) Peptidos humanos sinteticos y composiciones farmaceuticas que los contienen para el tratamiento de lupus eritematoso sistemico
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
PE20000177A1 (es) GEN dtsR TERMOSENSIBLE
ES2064374T3 (es) Escision especifica de enlaces peptidicos mediante fosfinas organicas que tienen cadenas laterales nucleofilas.
DK1108786T3 (da) Hidtil ukendt kollektin
ATE362769T1 (de) Lineare kationische peptide mit fungizider wirksamkeit
PE20000759A1 (es) Gen de la citocroma oxidasa de hidroquinona del tipo bd
DE69030293T2 (de) Neue Peptide, deren Intermediate, Verfahren zu deren Herstellung, antiallergische Agenzien, Vasodilatoren und Immunoregulatoren
DE69534738D1 (de) Leukocyten-aktivierender Faktor
CO5090903A1 (es) Nuevos peptidos para ser usados en una terapia de tolerancia inducida para impedir las alteraciones autoinmunes, en particular, artritis reumatoidea
ES2110671T3 (es) Procedimiento para la separacion de l-leucina y l-isoleucina de soluciones acuosas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 791011

Country of ref document: ES